COOK JEREMY CURNOCK 4

What Happened

Jeremy Curnock Cook, a director of AVITA Medical, received equity awards reported on a Form 4 covering June 3, 2026. The filing shows: 22,214 restricted stock units (RSUs) granted (time‑based) and 16,133 stock options granted with an exercise price of $3.77 per share. The option exercise price implies a cash outlay of about $60,821.41 to buy all 16,133 shares if exercised.

The RSUs vest 12 months after the January 20, 2026 grant date (i.e., on January 20, 2027). Both the RSU and option grants were subject to and received shareholder approval on June 3, 2026; the Form 4 was filed June 4, 2026.

Key Details

• Transaction types: A (award/grant). One RSU award (22,214 RSUs) and one option grant (16,133 options).
• Grant date: January 20, 2026. Shareholder approval: June 3, 2026. Filing date: June 4, 2026.
• Option exercise price: $3.77 per share; cash required to exercise all options ≈ $60,821.41.
• RSU vesting: 12 months after grant (Jan 20, 2027). RSUs represent contingent rights to receive shares on vesting.
• Shares owned after the transaction: not disclosed in the Form 4.
• Notable footnotes: RSUs are time‑based and include unvested RSUs; the option grant was part of director compensation approved by shareholders. No 10b5-1 or tax‑withholding details reported.
• Filing timeliness: Form 4 filed the day after shareholder approval; no late filing indicated.

Context

These entries are grants (compensation) rather than open‑market purchases or sales. RSUs are rights to be issued shares upon vesting; options must be exercised (paying the $3.77 strike) to obtain shares. Such director awards are routine compensation and do not by themselves indicate the director bought or sold shares in the open market.